Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
Trastuzumab-resistant
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "Trastuzumab-resistant" in MCE Product Catalog:
NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells .
Cat. No.: HY-164664
CAS No.: 2640038-22-6
Synonyms: CDK2-IN-30
Tudociclib is a CDK2 inhibitor with an IC50 value ≤20 nM. Tudociclib modulates CDK2 activity to influence cell cycle regulation. Tudociclib can be used for the research of cancer .
Cat. No.: HY-178275
CAS No.: 2694026-77-0
Target:
Research Areas:
Hydrotecan-NH-L-Ala-L-Val-L-Gln (CO-C5-succinimide)-D-glucitol is a Drug-Linker Conjugates for ADC, which can be used in studies related to ADC synthesis, such as the anti-HER2 antibody-drug conjugate MB-3a. The toxin moiety of Hydrotecan-NH-L-Ala-L-Val-L-Gln (CO-C5-succinimide)-D-glucitol is Hydrotecan (HY-164378), and the linker moiety is Mc-Glu (D-Glucamine)-val-ala (HY-178309) .
Cat. No.: HY-185718
Research Areas:
Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer .
Cat. No.: HY-185780
Synonyms: T-DM21
Target:
Research Areas:
Trastuzumab-DM12 (T-DM21) is an antibody-drug conjugate (ADC). Trastuzumab-DM12 binds to HER2, inhibits HER2 shedding, and mediates antibody-dependent cellular cytotoxicity. Trastuzumab-DM12 is formed by conjugating the antibody Trastuzumab (HY-P9907) with DM-21 (HY-139441). Trastuzumab-DM12 can be used for cancer research .
Cat. No.: HY-187653
CAS No.: 2556837-25-1
DCZ3112 is a Hsp90/Cdc37 protein-protein interaction inhibitor, with a Kd value of 4.98 µM against human Hsp90. DCZ3112 binds to the N-terminal domain of Hsp90, disrupts the Hsp90-Cdc37 interaction, and does not inhibit the ATPase activity of Hsp90. DCZ3112 induces G1 phase cell cycle arrest, apoptosis, reduces the phosphorylation levels of AKT and ERK, and inhibits the proliferation of HER2-positive breast cancer cells. DCZ3112 can be used in breast cancer-related research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
